These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. "Gadolinium-Phobia:" Not a Helpful "Criterion" for Indication for Gadolinium-based Contrast Agent Administration in Multiple Sclerosis. Goischke HK Radiology; 2016 Oct; 281(1):323-4. PubMed ID: 27643774 [No Abstract] [Full Text] [Related]
5. Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents. Gentili L; Capuano R; Gaetani L; Fiacca A; Bisecco A; d'Ambrosio A; Mancini A; Guercini G; Tedeschi G; Parnetti L; Gallo A; Di Filippo M J Neurol Sci; 2022 Nov; 442():120422. PubMed ID: 36162167 [No Abstract] [Full Text] [Related]
7. Is Gadolinium-based Contrast Material Needed for MRI Follow-up of Multiple Sclerosis? Saindane AM Radiology; 2019 May; 291(2):436-437. PubMed ID: 30860449 [No Abstract] [Full Text] [Related]
8. Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis. Forslin Y; Martola J; Bergendal Å; Fredrikson S; Wiberg MK; Granberg T AJNR Am J Neuroradiol; 2019 Aug; 40(8):1265-1273. PubMed ID: 31248867 [TBL] [Abstract][Full Text] [Related]
9. Do you believe in Gad? Maghzi AH; Sicotte NL; Waubant E Mult Scler Relat Disord; 2020 Sep; 44():102299. PubMed ID: 32593143 [No Abstract] [Full Text] [Related]
10. Routine Gadolinium Use for MRI Follow-Up of Multiple Sclerosis: Counterpoint-Gadolinium Should Not Always Be Used to Assess Disease Activity. Rovira À; Auger C AJR Am J Roentgenol; 2022 Jul; 219(1):26-27. PubMed ID: 34786958 [No Abstract] [Full Text] [Related]
11. Uncovering and characterizing multiple sclerosis lesions: the aid of fluid-attenuated inversion recovery images in the presence of gadolinium contrast agent. Bagnato F J Neuroimaging; 2009 Jul; 19(3):201-4. PubMed ID: 19187471 [No Abstract] [Full Text] [Related]
12. Reply to Letter to the Editor re: Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: Correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Stojanov DA Eur Radiol; 2016 Mar; 26(3):818-9. PubMed ID: 26391361 [No Abstract] [Full Text] [Related]
13. The usefulness of gadolinium-enhanced images on a follow-up magnetic resonance image in suspected multiple sclerosis. Moore FG; Levental M Can Assoc Radiol J; 2013 Nov; 64(4):358-62. PubMed ID: 23267520 [TBL] [Abstract][Full Text] [Related]
14. Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study. Forslin Y; Shams S; Hashim F; Aspelin P; Bergendal G; Martola J; Fredrikson S; Kristoffersen-Wiberg M; Granberg T AJNR Am J Neuroradiol; 2017 Jul; 38(7):1311-1316. PubMed ID: 28495943 [TBL] [Abstract][Full Text] [Related]
15. [The pharmacological economic analysis of application of magnetic resonance contrast mediums containing gadolinium in case of multiple sclerosis]. Shegay MM; Shimanovsky DN Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Mar; 29(2):343-346. PubMed ID: 33901380 [TBL] [Abstract][Full Text] [Related]
16. Brain MR post-gadolinium contrast in multiple sclerosis: the role of magnetization transfer and image subtraction in detecting more enhancing lesions. Gavra MM; Voumvourakis C; Gouliamos AD; Sfagos C; Vlahos LJ Neuroradiology; 2004 Mar; 46(3):205-10. PubMed ID: 14985887 [TBL] [Abstract][Full Text] [Related]